Income Insurance Ltd Makes New Investment in Merck & Co., Inc. $MRK

Income Insurance Ltd acquired a new position in shares of Merck & Co., Inc. (NYSE:MRK) during the 4th quarter, according to its most recent 13F filing with the SEC. The fund acquired 7,530 shares of the company’s stock, valued at approximately $793,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. United Financial Planning Group LLC purchased a new stake in Merck & Co., Inc. during the 3rd quarter worth approximately $31,000. Wealth Watch Advisors INC bought a new stake in shares of Merck & Co., Inc. in the 3rd quarter valued at approximately $34,000. Dunhill Financial LLC increased its holdings in shares of Merck & Co., Inc. by 83.0% in the 3rd quarter. Dunhill Financial LLC now owns 419 shares of the company’s stock valued at $35,000 after acquiring an additional 190 shares during the last quarter. Silicon Valley Capital Partners increased its holdings in shares of Merck & Co., Inc. by 160.5% in the 3rd quarter. Silicon Valley Capital Partners now owns 422 shares of the company’s stock valued at $35,000 after acquiring an additional 260 shares during the last quarter. Finally, J.Safra Asset Management Corp increased its holdings in shares of Merck & Co., Inc. by 53.6% in the 3rd quarter. J.Safra Asset Management Corp now owns 450 shares of the company’s stock valued at $38,000 after acquiring an additional 157 shares during the last quarter. 76.07% of the stock is currently owned by hedge funds and other institutional investors.

Merck & Co., Inc. Trading Down 0.9%

Shares of MRK stock opened at $111.26 on Friday. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.30 and a current ratio of 1.30. Merck & Co., Inc. has a 1 year low of $73.31 and a 1 year high of $125.14. The stock has a fifty day moving average of $117.07 and a two-hundred day moving average of $108.31. The firm has a market capitalization of $274.78 billion, a PE ratio of 31.34, a price-to-earnings-growth ratio of 2.51 and a beta of 0.18.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.19. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The company had revenue of $16.29 billion during the quarter, compared to analyst estimates of $15.85 billion. During the same quarter in the previous year, the firm posted $2.22 EPS. The firm’s quarterly revenue was up 4.9% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. As a group, research analysts expect that Merck & Co., Inc. will post 5.16 EPS for the current year.

Insiders Place Their Bets

In other Merck & Co., Inc. news, EVP Jennifer Zachary sold 121,573 shares of the business’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $119.15, for a total transaction of $14,485,422.95. Following the completion of the transaction, the executive vice president owned 68,916 shares in the company, valued at approximately $8,211,341.40. The trade was a 63.82% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CMO Chirfi Guindo sold 10,000 shares of the business’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $118.41, for a total value of $1,184,100.00. Following the transaction, the chief marketing officer owned 70,615 shares of the company’s stock, valued at $8,361,522.15. This trade represents a 12.40% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 0.17% of the company’s stock.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck published a landmark Science paper on a new large-scale biocatalytic synthesis method for its investigational oral PCSK9 inhibitor, enlicitide decanoate. The work supports manufacturing scalability for a potential future cardiovascular drug and underscores progress in Merck’s pipeline. Article Title
• Positive Sentiment: Merck also became the sole testing provider for Genetix Biotherapeutics’ FDA-approved gene therapies under a five-year agreement, strengthening its BioReliance services business and adding a recurring commercialization-related revenue stream. Article Title
• Neutral Sentiment: Analyst commentary highlighted Merck as a well-prepared dividend stock despite its upcoming patent cliff, suggesting the market is still weighing long-term earnings durability rather than reacting to a single catalyst. Article Title
• Negative Sentiment: Merck is heading toward a July 27 trial over Gardasil safety claims after the vaccine reached an $8.9 billion sales peak. The litigation risk could weigh on sentiment around one of Merck’s key growth franchises, even though the company continues to defend the product’s safety record. Article Title

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. Cantor Fitzgerald boosted their price target on Merck & Co., Inc. from $116.00 to $120.00 and gave the company a “neutral” rating in a report on Wednesday, February 4th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Merck & Co., Inc. in a report on Friday, May 1st. Wells Fargo & Company lowered their price target on Merck & Co., Inc. from $150.00 to $145.00 and set an “overweight” rating for the company in a report on Friday, May 1st. Zacks Research upgraded Merck & Co., Inc. from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 17th. Finally, Wall Street Zen upgraded Merck & Co., Inc. from a “hold” rating to a “buy” rating in a report on Saturday, March 28th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and seven have issued a Hold rating to the company. According to MarketBeat, Merck & Co., Inc. has an average rating of “Moderate Buy” and an average target price of $128.18.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.